Department of Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.
Department of Orthopedic and Traumatology, Faculty of Medicine, University of Hasanuddin, Makassar, Indonesia.
Asian Pac J Cancer Prev. 2023 May 1;24(5):1737-1741. doi: 10.31557/APJCP.2023.24.5.1737.
This study aimed to examine the expression of Histone H3.3 glycine 34 to tryptophan (G34W) mutant protein in Giant Cell Tumor of Bone (GCTB).
This analytic observation research used a cross-sectional study design on 71 bone tumors. The cases involved 54 tissue samples diagnosed as GCBT. It was divided into GCTB primer (n=37), recurrent GCTB (n=5), GCTB with metastasis (n=9), and malignant GCTB (n=3). There were 17 samples mimics of GCTB also tested, including chondroblastoma (n=1), giant cell reparative granuloma (n=2), giant cell of tendon sheath (n=7), chondromyxoid fibroma (n=2), aneurysmal bone cyst (n=2), and giant cell-rich osteosarcoma (n=3). The Immunohistochemistry was used to evaluate the expression of G34W-mutated protein in these bone tumors.
The representation H3.3 (G34W) was expressed in the nuclei of mononuclear stromal cells but not stained on osteoclast-like giant cells. This study was analyzed by the Chi-square test, Fisher's test, specificity test, and sensitivity test. We obtained p = 0.001 for Histone H3.3 (G34W) mutant expression in GCTB vs Non-GCTB. Statistically, there was no significant difference in the expression level of Histone H3.3 (G34W) in the GCTB and its variants p-value = 0.183. We also obtained that the specificity of Histone H3.3 expression on GCTB was 100% and the sensitivity of Histone H3.3 on GCTB was 77.8%.
Histon H3.3 mutant as a mutated driver gene in an Indonesian GCTB can assist to diagnose GCTB and compare it from other bone tumors.
本研究旨在研究骨巨细胞瘤(GCTB)中组蛋白 H3.3 甘氨酸 34 到色氨酸(G34W)突变蛋白的表达。
这是一项使用病例对照研究设计的分析观察性研究,共纳入 71 例骨肿瘤患者。其中 54 例组织学诊断为 GCTB,分为 GCTB 原发灶(n=37)、复发性 GCTB(n=5)、转移的 GCTB(n=9)和恶性 GCTB(n=3)。同时还纳入了 17 例 GCTB 模拟病例,包括软骨母细胞瘤(n=1)、巨细胞修复性肉芽肿(n=2)、腱鞘巨细胞瘤(n=7)、软骨黏液样纤维瘤(n=2)、动脉瘤样骨囊肿(n=2)和富含巨细胞的骨肉瘤(n=3)。采用免疫组织化学方法评估这些骨肿瘤中 G34W 突变蛋白的表达。
H3.3(G34W)在单核基质细胞的核中表达,但不染色破骨样巨细胞。通过卡方检验、Fisher 检验、特异性检验和敏感性检验对结果进行分析。我们发现 GCTB 中组蛋白 H3.3(G34W)突变表达与非 GCTB 相比有统计学差异(p=0.001)。GCTB 及其变体中组蛋白 H3.3(G34W)表达水平无统计学差异(p 值=0.183)。此外,组蛋白 H3.3 在 GCTB 中的特异性为 100%,敏感性为 77.8%。
在印度尼西亚 GCTB 中,组蛋白 H3.3 突变作为一种突变驱动基因,有助于诊断 GCTB,并与其他骨肿瘤进行比较。